BRPI0516048A - batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c - Google Patents
batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo cInfo
- Publication number
- BRPI0516048A BRPI0516048A BRPI0516048-0A BRPI0516048A BRPI0516048A BR PI0516048 A BRPI0516048 A BR PI0516048A BR PI0516048 A BRPI0516048 A BR PI0516048A BR PI0516048 A BRPI0516048 A BR PI0516048A
- Authority
- BR
- Brazil
- Prior art keywords
- adenovirus
- subgroup
- serotype
- batch
- defective recombinant
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 4
- 230000002950 deficient Effects 0.000 title abstract 2
- 230000003362 replicative effect Effects 0.000 title 1
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 abstract 2
- 101710176411 Coxsackievirus and adenovirus receptor Proteins 0.000 abstract 2
- 210000000234 capsid Anatomy 0.000 abstract 2
- 230000036039 immunity Effects 0.000 abstract 2
- 101710094396 Hexon protein Proteins 0.000 abstract 1
- 241000598171 Human adenovirus sp. Species 0.000 abstract 1
- 108091005899 fibrous proteins Proteins 0.000 abstract 1
- 102000034240 fibrous proteins Human genes 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
"BATELADA DE UM ADENOVìRUS RECOMBINANTE DEFECTIVO EM REPLICAçãO BASEADO EM UM SOROTIPO DO SUBGRUPO C". A presente invenção refere-se aos vetores adenovirais recombinantes baseados em adenovírus que encontram imunidade pré-existente em uma minoria da população humana e que hospedam um capsídeo quimérico. O capsídeo quimérico compreende proteínas fibrosas que possuem pelo menos o domínio de espícula de um adenovírus de humano que se liga em Receptor de Coxsackievírus e Adenovírus (CAR) e uma proteína hexon de um sorotipo de adenovírus que encontra imunidade pré-existente em uma minoria da população humana.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61846904P | 2004-10-13 | 2004-10-13 | |
EP04105005 | 2004-10-13 | ||
US69772405P | 2005-07-08 | 2005-07-08 | |
PCT/EP2005/055183 WO2006040330A2 (en) | 2004-10-13 | 2005-10-12 | Improved adenoviral vectors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0516048A true BRPI0516048A (pt) | 2008-08-19 |
Family
ID=35945186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516048-0A BRPI0516048A (pt) | 2004-10-13 | 2005-10-12 | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c |
Country Status (12)
Country | Link |
---|---|
US (1) | US7741099B2 (pt) |
EP (1) | EP1799836B1 (pt) |
KR (1) | KR101253363B1 (pt) |
AP (1) | AP2351A (pt) |
AU (1) | AU2005293568B2 (pt) |
BR (1) | BRPI0516048A (pt) |
CA (1) | CA2583843C (pt) |
EA (1) | EA010433B1 (pt) |
IL (1) | IL182330A (pt) |
MX (1) | MX2007004188A (pt) |
NZ (1) | NZ553889A (pt) |
WO (1) | WO2006040330A2 (pt) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
WO2006040330A2 (en) * | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
DK1994155T4 (da) | 2006-02-13 | 2022-07-25 | Daiichi Sankyo Co Ltd | Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
EP2185192B1 (en) | 2007-08-03 | 2018-10-31 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
WO2009065800A1 (en) * | 2007-11-20 | 2009-05-28 | Crucell Holland B.V. | Recombinant human adenoviruses for eliciting mucosal immune responses |
LT2340038T (lt) | 2008-10-10 | 2018-04-10 | Children`S Medical Center Corporation | Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina |
JP5770633B2 (ja) * | 2008-11-03 | 2015-08-26 | クルセル ホランド ベー ヴェー | アデノウイルスベクターの産生方法 |
US9017691B2 (en) | 2008-11-18 | 2015-04-28 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
US9555089B2 (en) | 2009-08-18 | 2017-01-31 | The Rockefeller University | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
WO2011129468A1 (en) | 2010-04-14 | 2011-10-20 | Mogam Biotechnology Research Institute | Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same |
AU2011343798B2 (en) * | 2010-12-14 | 2016-07-14 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
WO2012083297A2 (en) * | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
WO2012088041A1 (en) * | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
US20140348791A1 (en) * | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
WO2013090806A2 (en) | 2011-12-15 | 2013-06-20 | Washington University | Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection |
BR112014028684A2 (pt) | 2012-05-18 | 2017-07-25 | Univ Pennsylvania | subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos |
ES2723885T3 (es) | 2012-07-19 | 2019-09-03 | Daiichi Sankyo Co Ltd | Anticuerpos anti-Siglec-15 |
KR101429696B1 (ko) | 2012-11-21 | 2014-08-13 | 국립암센터 | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 |
CA2897059C (en) | 2013-01-07 | 2021-12-28 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same |
CA3115891A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
CN104419717B (zh) * | 2013-08-23 | 2018-04-27 | 长春百克生物科技股份公司 | 逃避预存免疫的重组腺病毒及其构建方法和用途 |
DK3052518T3 (da) | 2013-10-04 | 2020-04-06 | Beth Israel Deaconess Medical Ct Inc | Stabiliserede humant immundefektvirus-(hiv)-klade c-kappe-(env)-trimer-vacciner og fremgangsmåder til anvendelse deraf |
CA2926087C (en) | 2013-10-10 | 2023-03-14 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
BR112017005917A2 (pt) | 2014-09-26 | 2017-12-12 | Beth Israel Deaconess Medical Ct Inc | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana |
EP3328402A4 (en) | 2015-07-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | CHIMERIC ANTIGEN RECEPTORS EXPRESSING MODIFIED MONOCYTES / MACROPHAGES AND USES THEREOF |
EP3368067B1 (en) | 2015-10-30 | 2021-05-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Compositions and methods for the treatment of her2-expressing solid tumors |
EA038974B1 (ru) | 2015-12-15 | 2021-11-17 | Янссен Вэксинс Энд Превеншн Б.В. | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения |
EP3390428B1 (en) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN117384961A (zh) | 2016-02-23 | 2024-01-12 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
AU2017286375B2 (en) | 2016-06-16 | 2019-04-18 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
DK3512543T3 (da) | 2016-09-15 | 2020-10-12 | Janssen Vaccines & Prevention Bv | Trimerstabiliserende mutationer af hiv-kappeprotein |
EP3526236A4 (en) | 2016-10-17 | 2020-06-03 | Beth Israel Deaconess Medical Center, Inc. | SIGNATURE-BASED HUMAN IMMUNODEFICIENCY VIRUS VACCINES (ENV) CONTAINING SIGNS AND METHODS OF USE THEREOF |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
EA202090049A1 (ru) | 2017-06-15 | 2020-04-15 | Янссен Вэксинс Энд Превеншн Б.В. | Поксвирусные векторы, кодирующие антигены вич, и способы их применения |
DK3649237T3 (da) * | 2017-07-05 | 2022-02-21 | Nouscom Ag | Nukleinsyre- og aminosyresekvenser fra ikke-humant menneskeabe-adenovirus, vektorer indeholdende samme og anvendelser deraf |
AU2018304502B2 (en) | 2017-07-19 | 2022-03-31 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing HIV envelope protein mutations |
MX2020004488A (es) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus y usos de estos. |
JP7285833B2 (ja) | 2017-10-31 | 2023-06-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルス及びその用途 |
KR20200083510A (ko) | 2017-10-31 | 2020-07-08 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 및 이의 용도 |
KR20200074988A (ko) * | 2017-10-31 | 2020-06-25 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 벡터 및 이의 용도 |
WO2019099970A1 (en) | 2017-11-20 | 2019-05-23 | Janssen Pharmaceuticals Inc. | Method of providing safe administration of adenoviral vectors encoding a zika virus antigen |
CA3120715A1 (en) | 2018-11-21 | 2020-05-28 | Mayo Foundation For Medical Education And Research | Adenoviruses and methods for using adenoviruses |
CN113710694A (zh) | 2019-04-29 | 2021-11-26 | 梅奥医学教育及研究基金会 | 用于治疗癌症的多价pd-l1结合化合物 |
CN110564768A (zh) * | 2019-08-08 | 2019-12-13 | 广州佰芮慷生物科技有限公司 | 一种基于腺病毒HAd49的重组腺病毒表达载体及其构建方法 |
CN116096732A (zh) | 2020-01-31 | 2023-05-09 | 贝斯以色列护理医疗中心有限公司 | 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗 |
CA3183086A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
BR112022024228A2 (pt) | 2020-06-04 | 2023-02-07 | Carisma Therapeutics Inc | Construtos para receptores de antígeno quiméricos |
JP2023531554A (ja) | 2020-06-29 | 2023-07-24 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 呼吸器合胞体ウイルス感染に対するワクチンの組み合わせ |
BR112022026974A2 (pt) | 2020-07-06 | 2023-01-24 | Janssen Pharmaceuticals Inc | Proteínas de fusão estabilizadas de proteínas de pico de coronavírus |
US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
KR20230147156A (ko) | 2021-02-19 | 2023-10-20 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합 전 rsv fb 항원 |
WO2022207839A2 (en) | 2021-04-01 | 2022-10-06 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
EP4205759A1 (en) | 2022-01-04 | 2023-07-05 | Veterinärmedizinische Universität Wien | Fowl adenovirus subunit vaccine and production method thereof |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
AU773202B2 (en) * | 1998-08-27 | 2004-05-20 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
PT1054064E (pt) * | 1999-05-17 | 2005-02-28 | Crucell Holland Bv | Veiculos de entrega de genes derivados de adenovirus compreendendo pelo menos um elemento de adenovirus do tipo 35 |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
WO2001002607A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
AU9456201A (en) | 2000-09-15 | 2002-03-26 | Merck & Co Inc | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
BR0210586A (pt) | 2001-06-22 | 2005-07-12 | Wistar Inst | Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas |
JP4488290B2 (ja) | 2002-01-24 | 2010-06-23 | ザ・スクリップス・リサーチ・インスティテュート | 効率的ターゲティングのためのファイバーシャフト変異 |
AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
NZ539509A (en) | 2002-10-23 | 2008-05-30 | Glaxosmithkline Biolog Sa | Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine |
US6921582B2 (en) * | 2002-12-23 | 2005-07-26 | General Electric Company | Oxidation-resistant coatings bonded to metal substrates, and related articles and processes |
WO2004083418A1 (en) | 2003-03-17 | 2004-09-30 | Merck & Co., Inc. | Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby |
WO2006040330A2 (en) * | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
-
2005
- 2005-10-12 WO PCT/EP2005/055183 patent/WO2006040330A2/en active Application Filing
- 2005-10-12 AU AU2005293568A patent/AU2005293568B2/en not_active Ceased
- 2005-10-12 EP EP05815456A patent/EP1799836B1/en active Active
- 2005-10-12 NZ NZ553889A patent/NZ553889A/en not_active IP Right Cessation
- 2005-10-12 BR BRPI0516048-0A patent/BRPI0516048A/pt not_active IP Right Cessation
- 2005-10-12 KR KR1020077008494A patent/KR101253363B1/ko not_active IP Right Cessation
- 2005-10-12 MX MX2007004188A patent/MX2007004188A/es active IP Right Grant
- 2005-10-12 EA EA200700850A patent/EA010433B1/ru not_active IP Right Cessation
- 2005-10-12 US US11/665,276 patent/US7741099B2/en not_active Expired - Fee Related
- 2005-10-12 CA CA2583843A patent/CA2583843C/en not_active Expired - Fee Related
- 2005-10-12 AP AP2007003990A patent/AP2351A/xx active
-
2007
- 2007-03-29 IL IL182330A patent/IL182330A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA200700850A1 (ru) | 2007-08-31 |
CA2583843A1 (en) | 2006-04-20 |
KR20070085254A (ko) | 2007-08-27 |
AU2005293568B2 (en) | 2010-10-28 |
MX2007004188A (es) | 2007-10-11 |
EP1799836B1 (en) | 2010-12-22 |
AP2007003990A0 (en) | 2007-06-30 |
IL182330A (en) | 2013-02-28 |
EA010433B1 (ru) | 2008-08-29 |
AU2005293568A1 (en) | 2006-04-20 |
WO2006040330A3 (en) | 2006-08-24 |
WO2006040330A2 (en) | 2006-04-20 |
KR101253363B1 (ko) | 2013-04-15 |
IL182330A0 (en) | 2007-07-24 |
AP2351A (en) | 2012-01-25 |
CA2583843C (en) | 2010-09-21 |
US7741099B2 (en) | 2010-06-22 |
US20080199939A1 (en) | 2008-08-21 |
EP1799836A2 (en) | 2007-06-27 |
NZ553889A (en) | 2009-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0516048A (pt) | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c | |
ATE492643T1 (de) | Verbesserte adenovirusvektoren und deren verwendung | |
WO2001050280A3 (en) | System and method for providing hot swap capability using existing circuits and drivers with minimal changes | |
Friesen et al. | SMN, the product of the spinal muscular atrophy gene, binds preferentially to dimethylarginine-containing protein targets | |
Zhang et al. | Role of the calcium-calpain pathway in cytoskeletal damage after eccentric contractions | |
RS51250B (sr) | Modifikovani hekson protein adenovirusa i njegova upotreba | |
DK1252192T3 (da) | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid | |
Chesnokova et al. | Epstein-Barr virus infection mechanisms | |
MX2012012927A (es) | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). | |
ATE398676T2 (de) | Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins | |
BR122019013216B8 (pt) | ensaio imunológico para análise de uma vacina contra influenza | |
AR079274A1 (es) | Proteinas de enlace a antigenos (humanas) que enlazan (beta)-klotho, receptores fgf y complejo de los mismos | |
ATE516343T1 (de) | Zellinien zur produktion von replikationsdefektem adenovirus | |
Peyron et al. | Effects of heat treatment and pectin addition on β-lactoglobulin allergenicity | |
BR0305995A (pt) | Controle de identificador para marcas de brilho (glossmark) em tempo de execução | |
ATE389397T1 (de) | Adjuvante zusammensetzungen | |
WO2005113838A3 (en) | Detection of protein translocation by beta-galactosidase reporter fragment complementation | |
WO2008048976A3 (en) | Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors | |
Patella et al. | Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis | |
BRPI0415277A (pt) | célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo | |
WO2001092547A3 (en) | Modified bovine adenovirus having altered tropism | |
Crisci et al. | Immune characterization of long pentraxin 3 in pigs infected with influenza virus | |
BR0212287A (pt) | Proteìna de ligação caspase-8, sua preparação e uso | |
DE602005002725D1 (de) | Druckgerät | |
Kumar et al. | Effect of ambient temperature on respiratory tract cells exposed to SARS-CoV-2 viral mimicking nanospheres—An experimental study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |